Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

VanEck Vectors Pharmaceutical ETF (PPH)

62.63
Delayed Data
As of Jan 18
 -0.47 / -0.74%
Today’s Change
50.91
Today|||52-Week Range
63.47
+5.60%
Year-to-Date

Investment Objective

The investment seeks to replicate as closely as possible- before fees and expenses- the price and yield performance of the MVIS-¤ US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Pharmaceutical Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

No recent news for VanEck Vectors Pharmaceutical ETF.

Performance

1 month+5.05% 3 years+0.02%
3 months+8.61% 5 years+10.66%
1 year+21.06% Since inception+11.99%
Data through 01/19/2018

Quote Details

Previous close$63.10
Open day’s range62.26 – 62.80
Net asset value (NAV)62.61 (01/18/2018)
Daily volume841,500
Average volume (3 months)65,580
Data as of 3:59pm ET, 01/18/2018

Peer Comparisonvs. Health ETFs

 PPHCategory
Performance 5-yr return+10.66%+17.28%
Expense Gross exp ratio0.41%1.32%
Risk 5 year sharpe ratio0.781.11
Net assets$284.2M$3.0B
Average market cap$42.1B$9.3B
Average P/E18.721.8
Dividend / Share--0.33%

Competitors

XLV Health Care Select Sector SPDR® Fund
RYH Guggenheim S&P 500® Equal Weight Health...
FHLC Fidelity® MSCI Health Care Index ETF
VHT Vanguard Health Care Index Fund ETF Shar...

Holdings

Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
TEVA Teva Pharmaceutical5.64%
AZN AstraZeneca5.11%
-- 5.03%
MRK Merck4.90%
NVO Novo Nordisk4.87%
MYL Mylan NV4.86%
GSK GlaxoSmithKline4.85%
ABBV AbbVie4.83%
PFE Pfizer4.81%
NVS Novartis4.77%